<DOC>
	<DOCNO>NCT00700258</DOCNO>
	<brief_summary>The purpose registry obtain general view regard efficacy , tolerability safety issue Torisel® , Sutent® , and/or Inlyta® therapies patient advance renal cell carcinoma , recurrent / refractory mantle cell lymphoma ( MCL ) gastro-intestinal stroma tumor ( GIST ) condition routine use</brief_summary>
	<brief_title>Registry For Temsirolimus , Sunitinib , And Axitinib Treated Patients With Metastatic Renal Cell Carcinoma ( mRCC ) , Mantle Cell Lymphoma ( MCL ) , And Gastro-Intestinal Stroma Tumor ( GIST ) STAR-TOR</brief_title>
	<detailed_description>Treatment metastatic renal cell carcinoma ( mRCC ) experience fundamental change within short period time . In past year , introduction various new substance treatment mRCC therefore result new scientific research question . Temsirolimus sunitinib current standard therapy first-line treatment mRCC . Inlyta® new substance develop treatment mRCC failure sunitinib cytokine . Since August 2009 , Torisel® available another treatment option patient mantle cell lymphoma ( MCL ) . In addition , Sutent® use patient non-resectable / metastatic gastro-intestinal stroma tumor ( GIST ) failure intolerability imatinib . The routine use drug usual clinical setting face additional challenge generally completely reflected clinical trial . Therefore , purpose registry obtain general view regard efficacy , tolerability safety issue Torisel® , Sutent® , and/or Inlyta® therapies patient advance renal cell carcinoma , recurrent / refractory mantle cell lymphoma ( MCL ) gastro-intestinal stroma tumor ( GIST ) condition routine use . Therefore , follow information particular interest course investigation : - Efficacy ( best response , overall survival , progression-free survival ) - Tolerability therapy ( assessed physician ) - Safety profile ( overall incidence adverse event well side-effect rate ) subject mRCC , rMCL , GIST treatment Torisel® , Sutent® , and/or Inlyta® - Profile , comorbidities , characteristic subject treat Torisel® Sutent® , and/or Inlyta® - The sequence use systemic therapy RCC , MCL , GIST - Patient survey quality life mRCC patient</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<mesh_term>Axitinib</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Patients proven tumor RCC , MCL GIST histology . Informed consent sign patient . Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>